Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal
Executive Summary
Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S
You may also be interested in...
AbbVie’s Battle Over Alvotech’s Humira Biosimilar Moves To New Ground With ITC Investigation
International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.
AbbVie’s Battle Over Alvotech’s Biosimilar Humira Moves To New Ground With ITC Investigation
International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.
Court May Ask Roche To Pay Amgen 22.5 Percent Mircera Marketing Royalty
Preliminary injunction bars launch of Roche’s Mircera; suggests terms to avoid a permanent injunction.